A61K 40/4207
Platelet-derived growth factor receptors [pdgfr]
Official title: {Platelet-derived growth factor receptors [PDGFR]}
A61K40/4207 (Platelet-derived growth factor receptors [pdgfr]) appears on 2 US grants and 6 published applications in this corpus.
Search patents in A61K- Granted patents
- 2
- Published applications
- 6
- Assignees
- 5
- Inventors
- 14
- Latest grant
- 22 Oct 2019
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 2 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 0 |
| 2020 | 0 | 1 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- Genetically engineered antibody resistant (gear) cells for adoptive cellular therapy26 Jun 2025US 2025/0205282 A1VyGen-Bio, Inc.
- Use of a stromal antigen to deliver cell-based cancer therapy to a solid tumor17 Oct 2024US 2024/0342281 A1The Regents of the University of California
- Delivery methods and compositions for nuclease-mediated genome engineering2 Apr 2020US 2020/0102577 A1Sangamo Therapeutics, Inc.
- Delivery methods and compositions for nuclease-mediated genome engineering19 Jan 2017US 2017/0016027 A1Sangamo Therapeutics, Inc.
- Anticancer Agent Containing Minus-Strand Rna Virus7 Feb 2008US 2008/0031855 A1DNAVEC Research Inc.
Most cited
By later US patents